Anus disorder

Summary

Anus disorder (MONDO:0002519) is a disease (an umbrella term covering 7 Mondo subtypes) and 2 clinical trials. Top therapeutic interventions include hyaluronic acid and sulfadiazine, silver. A subtype of rectal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 7 Mondo subtypes
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anus disorder
Mondo ID	MONDO:0002519
EFO	EFO:0009660
MeSH	D001004
DOID	DOID:3128
NCIT	C26695
SNOMED CT	32110003
UMLS	C0003462
MedGen	359
Anatomy (UBERON)	UBERON:0001245
Is cancer (heuristic)	no

Also known as: anal disorder · anus disease · anus disease or disorder · disease of anus · disease or disorder of anus · disorder of anal region · disorder of anus

Disease family

This is a subtype of rectal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › rectal disorder › anus disorder

Related subtypes (5): anal fistula, ulcer of anus and rectum, rectal neoplasm, rectal prolapse, polyp of rectum

Subtypes (7): imperforate anus, anorectal stricture, anal spasm, anus neoplasm, proctitis, levator syndrome, anal polyp

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Fibrin	Phase 3 (in late-stage trials)
Nitroglycerin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Diltiazem, Lidocaine, Nifedipine.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06872151	PHASE4	COMPLETED	Evaluation of the Effectiveness of a Topical Medical Device in Wound Healing and Symptom Relief in the Postoperative Period of Open Excisional Hemorrhoidectomy (The Emor Study)
NCT02526953	PHASE3	UNKNOWN	Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
HYALURONIC ACID	4	1
SULFADIAZINE, SILVER	4	1